Abstract
D ESPITE intense and repeated antirejective therapy with triple combinations of cyclosporine A (CyA), cortisone (CORT), antithymocyte globuline (ATG), and consecutive monoclonal CD3 antibodies (OKT3) in acute rejection episodes, still confront transplant recipients who have relapses of acute rejection (AR). In a patient subset after allogenic TX we asked (1). Can this recipient group be characterized by risk factors? and (2) Is there an efficacious regimen for safe therapy of recurrent rejection episodes?
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
